These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

635 related articles for article (PubMed ID: 29781109)

  • 1. Rate pressure product and the components of heart rate and systolic blood pressure in hospitalized heart failure patients with preserved ejection fraction: Insights from ASCEND-HF.
    Verma AK; Sun JL; Hernandez A; Teerlink JR; Schulte PJ; Ezekowitz J; Voors A; Starling R; Armstrong P; O'Conner CM; Mentz RJ
    Clin Cardiol; 2018 Jul; 41(7):945-952. PubMed ID: 29781109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial.
    Ambrosy AP; Vaduganathan M; Mentz RJ; Greene SJ; Subačius H; Konstam MA; Maggioni AP; Swedberg K; Gheorghiade M
    Am Heart J; 2013 Feb; 165(2):216-25. PubMed ID: 23351825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure: From the ASCEND-HF Trial.
    Greene SJ; Hernandez AF; Dunning A; Ambrosy AP; Armstrong PW; Butler J; Cerbin LP; Coles A; Ezekowitz JA; Metra M; Starling RC; Teerlink JR; Voors AA; O'Connor CM; Mentz RJ
    J Am Coll Cardiol; 2017 Jun; 69(25):3029-3039. PubMed ID: 28641792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in blood pressure riser pattern in patients with acute heart failure with reduced mid-range and preserved ejection fraction.
    Ueda T; Kawakami R; Nakada Y; Nakano T; Nakagawa H; Matsui M; Nishida T; Onoue K; Soeda T; Okayama S; Watanabe M; Okura H; Saito Y
    ESC Heart Fail; 2019 Oct; 6(5):1057-1067. PubMed ID: 31325235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential impact of heart rate and blood pressure on outcome in patients with heart failure with reduced versus preserved left ventricular ejection fraction.
    Maeder MT; Kaye DM
    Int J Cardiol; 2012 Mar; 155(2):249-56. PubMed ID: 21035207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relation of Systolic Blood Pressure on the Following Day with Post-Discharge Mortality in Hospitalized Heart Failure Patients with Preserved Ejection Fraction.
    Sato Y; Yoshihisa A; Oikawa M; Nagai T; Yoshikawa T; Saito Y; Yamamoto K; Takeishi Y; Anzai T
    Int Heart J; 2019 Jul; 60(4):876-885. PubMed ID: 31257340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
    Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
    Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Worsening heart failure during hospitalization for acute heart failure: Insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF).
    Kelly JP; Mentz RJ; Hasselblad V; Ezekowitz JA; Armstrong PW; Zannad F; Felker GM; Califf RM; O'Connor CM; Hernandez AF
    Am Heart J; 2015 Aug; 170(2):298-305. PubMed ID: 26299227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between left ventricular ejection fraction and mortality in patients with acute heart failure: insights from the ASCEND-HF Trial.
    Toma M; Ezekowitz JA; Bakal JA; O'Connor CM; Hernandez AF; Sardar MR; Zolty R; Massie BM; Swedberg K; Armstrong PW; Starling RC
    Eur J Heart Fail; 2014 Mar; 16(3):334-41. PubMed ID: 24464687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of heart rate changes during hospitalization on outcome in heart failure with preserved ejection fraction.
    Liu D; Cui X; Xu Y; Xu L; Xie Z; Yuan S; Wang P; Wang Y; Qian S; Gong H; Nordbeck P; Yang J; Zhou J; Ge J; Sun A
    ESC Heart Fail; 2024 Oct; 11(5):2901-2912. PubMed ID: 38514992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction.
    Salah K; Stienen S; Pinto YM; Eurlings LW; Metra M; Bayes-Genis A; Verdiani V; Tijssen JGP; Kok WE
    Heart; 2019 Aug; 105(15):1182-1189. PubMed ID: 30962192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systolic Blood Pressure and Outcomes in Patients With Heart Failure With Preserved Ejection Fraction.
    Tsimploulis A; Lam PH; Arundel C; Singh SN; Morgan CJ; Faselis C; Deedwania P; Butler J; Aronow WS; Yancy CW; Fonarow GC; Ahmed A
    JAMA Cardiol; 2018 Apr; 3(4):288-297. PubMed ID: 29450487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of hyponatremia among ambulatory patients with heart failure and preserved and reduced ejection fractions.
    Bavishi C; Ather S; Bambhroliya A; Jneid H; Virani SS; Bozkurt B; Deswal A
    Am J Cardiol; 2014 Jun; 113(11):1834-8. PubMed ID: 24837261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of elevated heart rate on clinical outcomes in patients with heart failure with reduced and preserved ejection fraction: a report from the CHART-2 Study.
    Takada T; Sakata Y; Miyata S; Takahashi J; Nochioka K; Miura M; Tadaki S; Shimokawa H;
    Eur J Heart Fail; 2014 Mar; 16(3):309-16. PubMed ID: 24464774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Role of Prior Heart Failure Hospitalization Among Patients Hospitalized for Worsening Chronic Heart Failure.
    Blumer V; Mentz RJ; Sun JL; Butler J; Metra M; Voors AA; Hernandez AF; O'Connor CM; Greene SJ
    Circ Heart Fail; 2021 Apr; 14(4):e007871. PubMed ID: 33775110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recovered heart failure with reduced ejection fraction and outcomes: a prospective study.
    Lupón J; Díez-López C; de Antonio M; Domingo M; Zamora E; Moliner P; González B; Santesmases J; Troya MI; Bayés-Genís A
    Eur J Heart Fail; 2017 Dec; 19(12):1615-1623. PubMed ID: 28387002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of characteristics and outcomes of patients with heart failure preserved ejection fraction versus reduced left ventricular ejection fraction in an urban cohort.
    Quiroz R; Doros G; Shaw P; Liang CS; Gauthier DF; Sam F
    Am J Cardiol; 2014 Feb; 113(4):691-6. PubMed ID: 24484862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of N-terminal pro C-type natriuretic peptide in heart failure patients with preserved and reduced ejection fraction.
    Lok DJ; Klip IT; Voors AA; Lok SI; Bruggink-André de la Porte PW; Hillege HL; Jaarsma T; van Veldhuisen DJ; van der Meer P
    Eur J Heart Fail; 2014 Sep; 16(9):958-66. PubMed ID: 25082741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of systolic blood pressure in acute heart failure with preserved ejection fraction in older patients.
    Putot S; Hacquin A; Manckoundia P; Putot A
    ESC Heart Fail; 2021 Dec; 8(6):5493-5500. PubMed ID: 34664426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models.
    Khazanie P; Heizer GM; Hasselblad V; Armstrong PW; Califf RM; Ezekowitz J; Dickstein K; Levy WC; McMurray JJ; Metra M; Tang WH; Teerlink JR; Voors AA; O'Connor CM; Hernandez AF; Starling R
    Am Heart J; 2015 Aug; 170(2):290-7. PubMed ID: 26299226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.